The potent effects of fascin upregulation has motivated the development of small-molecule fascin inhibitors, which have shown promise as cancer therapeutics in preclinical mouse models and are undergoing phase 2 clinical trials for treatment of gynecological and breast cancers42–44. This evidence concerns the gene FSCN1 and neoplasm.